STEMLINE THERAPEUTICS INC Form 8-K November 15, 2013

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of report (Date of earliest event reported): November 13, 2013

Stemline Therapeutics, Inc.

(Exact Name of Registrant as Specified in Charter)

Delaware 001-35619 45-0522567

(State or Other Jurisdiction (Commission File Number) (IRS Employer Identification No.)
of Incorporation)

750 Lexington Avenue

Eleventh Floor

New York, New York 10022

(Address of Principal Executive Offices)

(646) 502-2311

(Registrant s telephone number, including area code)

Check the appropria the following provis	te box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of ions:
o	Written communications pursuant to Rule 425 under the Securities Act.
0	Soliciting material pursuant to Rule 14a-12 under the Exchange Act.
o	Pre-commencement communications pursuant to Rule 14d-2b under the Exchange Act.
0	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

Item 5.02.	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officer
Compensatory Arrangements	of Certain Officers.

b) On November 13, 2013, Stephen P. Hall resigned as Vice President, Finance and Chief Accounting Officer of Stemline Therapeutics, Inc. Such resignation will be effective as of November 30, 2013.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Stemline Therapeutics, Inc.

(Registrant)

Date: November 15, 2013

By: /s/ Kenneth Hoberman

Kenneth Hoberman Chief Operating Officer

3